2023
Persistence on Novel Cardioprotective Antihyperglycemic Therapies in the United States
Nargesi A, Clark C, Aminorroaya A, Chen L, Liu M, Reddy A, Amodeo S, Oikonomou E, Suchard M, McGuire D, Lin Z, Inzucchi S, Khera R. Persistence on Novel Cardioprotective Antihyperglycemic Therapies in the United States. The American Journal Of Cardiology 2023, 196: 89-98. PMID: 37012183, PMCID: PMC11007258, DOI: 10.1016/j.amjcard.2023.03.002.Peer-Reviewed Original ResearchConceptsSGLT-2iGLP-1RAsGlucagon-like peptide-1 receptor agonistsUnited States administrative claims databasesSodium-glucose cotransporter 2 inhibitorsCommercial insurancePeptide-1 receptor agonistsType 2 diabetes mellitusSodium-glucose cotransporter-2 inhibitorsConsistent medication useHealth outcome benefitsCotransporter 2 inhibitorsElevated cardiovascular riskInitiation of therapyAdministrative claims databaseProportion of daysCotransporter-2 inhibitorsRate of prescriptionAntihyperglycemic therapyCardiovascular riskDiabetes mellitusMedication useCardioprotective effectsPrescription practicesClaims database
2022
Phenomapping-Derived Tool to Individualize the Effect of Canagliflozin on Cardiovascular Risk in Type 2 Diabetes.
Oikonomou EK, Suchard MA, McGuire DK, Khera R. Phenomapping-Derived Tool to Individualize the Effect of Canagliflozin on Cardiovascular Risk in Type 2 Diabetes. Diabetes Care 2022, 45: 965-974. PMID: 35120199, PMCID: PMC9016734, DOI: 10.2337/dc21-1765.Peer-Reviewed Original ResearchConceptsCanagliflozin Cardiovascular Assessment StudyMajor adverse cardiovascular eventsType 2 diabetesHazard ratioSodium-glucose cotransporter 2 inhibitorsCardiovascular disease benefitAdverse cardiovascular eventsCotransporter 2 inhibitorsEffects of canagliflozinCanagliflozin dosesCanagliflozin's effectsCardiovascular eventsCardiovascular riskPatients 5Cardioprotective effectsSGLT2 inhibitorsDisease benefitBaseline variablesOriginal trialCanagliflozinType 2DiabetesPatientsRisk estimatesEffect estimates
2019
Association of Biologic Therapy With Coronary Inflammation in Patients With Psoriasis as Assessed by Perivascular Fat Attenuation Index
Elnabawi YA, Oikonomou EK, Dey AK, Mancio J, Rodante JA, Aksentijevich M, Choi H, Keel A, Erb-Alvarez J, Teague HL, Joshi AA, Playford MP, Lockshin B, Choi AD, Gelfand JM, Chen MY, Bluemke DA, Shirodaria C, Antoniades C, Mehta NN. Association of Biologic Therapy With Coronary Inflammation in Patients With Psoriasis as Assessed by Perivascular Fat Attenuation Index. JAMA Cardiology 2019, 4: 885-891. PMID: 31365032, PMCID: PMC6669789, DOI: 10.1001/jamacardio.2019.2589.Peer-Reviewed Original ResearchConceptsPerivascular fat attenuation indexFat attenuation indexBiologic psoriasis therapyBiologic therapyCoronary inflammationSevere psoriasisPsoriasis therapyCoronary plaquesSkin diseasesAnti-tumor necrosis factor αChronic inflammatory skin diseaseDifferent biologic agentsTraditional risk scoresCoronary plaque burdenLow cardiovascular riskProspective cohort studyAnti-inflammatory effectsCoronary artery diseaseInflammatory skin diseaseCoronary atherosclerotic plaquesNecrosis factor αSevere skin diseaseCardiovascular eventsCardiovascular riskCohort study
2018
Development and Validation of a Clinical Score for Cardiovascular Risk Stratification of Long‐Term Childhood Cancer Survivors
Oikonomou EK, Athanasopoulou SG, Kampaktsis PN, Kokkinidis DG, Papanastasiou CA, Feher A, Steingart RM, Oeffinger KC, Gupta D. Development and Validation of a Clinical Score for Cardiovascular Risk Stratification of Long‐Term Childhood Cancer Survivors. The Oncologist 2018, 23: 965-973. PMID: 29593100, PMCID: PMC6156177, DOI: 10.1634/theoncologist.2017-0502.Peer-Reviewed Original ResearchConceptsLong-term childhood cancer survivorsChildhood cancer survivorsCardiovascular risk stratificationCardiovascular mortalityCancer survivorsRisk scoreCardiovascular riskRisk stratificationRisk of CVMTreatment-related adverse eventsAdverse cardiovascular eventsRisk stratification toolSimple risk scoreCongestive heart failureCumulative incidence rateEnd Results ProgramMedian time periodPopulation-based studyHistory of lymphomaHigh-risk groupLow-risk groupSimple clinical toolHistory of radiationNon-white raceHealth care providers
2017
Vascular inflammation and metabolic activity in hematopoietic organs and liver in familial combined hyperlipidemia and heterozygous familial hypercholesterolemia
Toutouzas K, Skoumas J, Koutagiar I, Benetos G, Pianou N, Georgakopoulos A, Galanakos S, Antonopoulos A, Drakopoulou M, Oikonomou EK, Kafouris P, Athanasiadis E, Metaxas M, Spyrou G, Pallantza Z, Galiatsatos N, Aggeli C, Antoniades C, Keramida G, Peters AM, Anagnostopoulos CD, Tousoulis D. Vascular inflammation and metabolic activity in hematopoietic organs and liver in familial combined hyperlipidemia and heterozygous familial hypercholesterolemia. Journal Of Clinical Lipidology 2017, 12: 33-43. PMID: 29174439, DOI: 10.1016/j.jacl.2017.10.019.Peer-Reviewed Original ResearchMeSH KeywordsAdultBiomarkersBone MarrowC-Reactive ProteinCase-Control StudiesFemaleHeterozygoteHumansHydroxymethylglutaryl-CoA Reductase InhibitorsHyperlipidemia, Familial CombinedHyperlipoproteinemia Type IIInflammationLipoproteins, LDLLiverMaleMiddle AgedPositron Emission Tomography Computed TomographySpleenConceptsHeFH patientsFDG uptakeAortic TBRVascular inflammationBone marrowFamilial dyslipidemiaHigher low-density lipoprotein levelsF-fluorodeoxyglucose positron emission tomography/High-sensitivity C-reactive proteinBone marrow FDG uptakeLow-density lipoprotein levelsPositron emission tomography/C-reactive proteinHigh FDG uptakeHeterozygous familial hypercholesterolemiaLow-density lipoproteinHepatic metabolic activityHematopoietic organsHigh liver uptakeDyslipidemic groupAdult patientsCardiovascular riskInflammatory biomarkersSerum lipidsAccelerated atherogenesis